Drug Profile
BtX 13 - EpimedX
Alternative Names: BtX-13Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator EpimedX
- Class Plant proteins
- Mechanism of Action Fetal haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Beta-thalassaemia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Beta-thalassaemia in USA (Parenteral)
- 10 Aug 2016 Early research in Beta-thalassaemia in USA (Parenteral)